http://jbx.sagepub.com/Journal of Biomolecular Screening

http://jbx.sagepub.com/content/16/8/886The online version of this article can be found at:

 DOI: 10.1177/1087057111414896

2011 16: 886 originally published online 10 August 2011J Biomol ScreenKrisztina Herédi-Szabó, Tibor Abonyi, István Krizbai, Gábor K. Tóth and Péter Krajcsi

István Sziráki, Franciska Erdo, Erzsébet Beéry, Petra Magdolna Molnár, Csilla Fazakas, Imola Wilhelm, Ildikó Makai, Emese Kis,Correlation Study

Brain Barrier: An In Vitro In Vivo−Quinidine as an ABCB1 Probe for Testing Drug Interactions at the Blood  

Published by:

http://www.sagepublications.com

On behalf of: 

  Journal of Biomolecular Screening

can be found at:Journal of Biomolecular ScreeningAdditional services and information for    

  http://jbx.sagepub.com/cgi/alertsEmail Alerts:

 

http://jbx.sagepub.com/subscriptionsSubscriptions:  

http://www.sagepub.com/journalsReprints.navReprints:  

http://www.sagepub.com/journalsPermissions.navPermissions:  

What is This? 

- Aug 10, 2011 OnlineFirst Version of Record 

- Sep 9, 2011Version of Record >>

by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from by guest on October 11, 2013jbx.sagepub.comDownloaded from

886 www.slas.org © 2011 Society for Laboratory Automation and Screening

IntroductIon

Drug efflux transporters of the adenosine triphos-

phate (atp)-binding cassette-containing proteins have a major role in the transport of clinically relevant drugs. abCb1/ p-glycoprotein (p-gp)/Mdr1, one of the most important efflux transporters, is present in the apical membranes of endothelial/epithelial cells of the tissues with barrier function, the blood–brain barrier (bbb) among them. abCb1 substrates are translo-cated from the basolateral to the apical side of the cells (for review, see schinkel and Jonker1). abCb1 prevents brain pen-etration of substrate drugs, and abCb1 inhibition may lead to increased brain exposure and Cns toxicity. therefore, testing

for abCb1-mediated drug interaction is important to assess the toxicity potential of coadministered drugs.

digoxin is the prototypic abCb1 probe substrate recom-mended by the regulatory agencies.2,3 however, a consensus has not been reached on this issue.4 Quinidine is also considered an abCb1-specific probe.4 several studies suggest that the entry of quinidine into the brain is restricted5 and controlled by abCb1 expressed in the bbb.6–8 Yet, even in recent reviews, quinidine is classified as an abCb1 inhibitor.2,9 the aim of the present study was to provide further evidence that quinidine can be used as a probe substrate for abCb1 at the bbb employing a battery of test systems, including membrane assays, cell-based assays, and dual-/triple-probe microdialysis assays in anesthetized and awake rats. We propose using quinidine and psC-833 (valspodar), a clinically relevant abCb1 inhibitor,10,11 as a probe substrate/reference inhib-itor combination to assess investigational drugs for their interac-tions on abCb1 in the in vitro and in vivo bbb models.

MAterIALS And MethodS

Chemicals and supplies for in vitro and in vivo assays

Quinidine, fetal calf serum (fCs), Cpt-caMp, hydrocortisone, collagen type iV, fibronectin, heparin, insulin-transferrin-sodium selenite media supplement, and puromycin were purchased from

1solvo biotechnology, szeged, hungary.2department of biochemistry, faculty of Medicine, university of szeged, hungary.3institute of biophysics, biological research Center, szeged, hungary.4department of Medical Chemistry, faculty of Medicine, university of szeged, szeged, hungary.5trans-neuropharma ltd, budapest, hungary.

received Jan 26, 2011, and in revised form May 13, 2011. accepted for publi-cation May 25, 2011.

Journal of biomolecular screening 16(8); 2011doi: 10.1177/1087057111414896

Quinidine as an ABcB1 Probe for testing drug Interactions at the Blood–Brain Barrier: An In Vitro

In Vivo correlation Study

IStVán SzIrákI,1 FrAncISkA erdo,1 erzSéBet Beéry,1 PetrA MAgdoLnA MoLnár,2 cSILLA FAzAkAS,3 IMoLA WILheLM,3 ILdIkó MAkAI,1 eMeSe kIS,1 krISztInA herédI-SzABó,1

tIBor ABonyI,1 IStVán krIzBAI,3 gáBor k. tóth,4 and Péter krAjcSI1

this study provides evidence that quinidine can be used as a probe substrate for abCb1 in multiple experimental systems both in vitro and in vivo relevant to the blood–brain barrier (bbb). the combination of quinidine and psC-833 (valspodar) is an effective tool to assess investigational drugs for interactions on abCb1. effects of quinidine and substrate–inhibitor interac-tions were tested in a membrane assay and in monolayer assays. the authors compared quinidine and digoxin as abCb1 probes in the in vitro assays and found that quinidine was more potent and at least as specific as digoxin in atpase and monolayer efflux assays employing MdCKii-Mdr1 and the rat brain microcapillary endothelial cell system. brain exposure to quinidine was tested in dual-/triple-probe microdialysis experiments in rats by assessing levels of quinidine in blood and brain. Comparing quinidine levels in dialysate samples from valspodar-treated and control animals, it is evident that systemic/local administration of the inhibitor diminishes the pumping function of abCb1 at the bbb, resulting in an increased brain pen-etration of quinidine. in sum, quinidine is a good probe to study abCb1 function at the bbb. Moreover, quinidine/psC-833 is an abCb1-specific substrate/inhibitor combination applicable to many assay systems both in vitro and in vivo. (Journal of Biomolecular Screening 2011;16:886-894)

key words: bbb, abCb1/p-gp, quinidine, psC-833, microdialysis

Quinidine as an ABcB1 Probe for the Blood–Brain Barrier

journal of Biomolecular Screening 16(8); 2011 www.slas.org 887

sigma (sigma-hungary Kft, budapest, hungary). ro-201724 was purchased from roche (roche hungary Kft, budaörs, hungary). Quinidine (9-3h) was purchased from american radiolabeled Chemicals (st. louis, Mo). psC-833 and the Mdr1 predeasY atpase assay kit were supplied by solvo biotechnology (szeged, hungary). lY-335979 was synthe-sized as described earlier.12 for monolayer assays, the Millicell 24 device from Millipore (Millipore Kft, budapest, hungary), dulbecco’s modified eagle’s medium (dMeM)/f12 from invitrogen (Csertex Kft, budapest, hungary), bfgf from roche (roche hungary Kft), plasma-derived serum (pds) from first link (birmingham, uK), and transwell filters from Costar Corning (Zenon bio Kft, szeged, hungary) were applied. Microdialysis probes, tubing adapters, and guide can-nulae (CMa, solna, sweden) were obtained from atmos hörka Kft (budapest, hungary). fep and peeK tubings and sample vials were obtained from Microbiotech (stockholm, sweden).

In vitro assays

ATPase assay. the Mdr1 predeasY atpase assay kit (solvo biotechnology) was used. the assay was performed as suggested by the manufacturer with the following modifica-tions: in activation experiments, quinidine or digoxin was applied at increasing concentrations (0.2–800 µM and 0.37–800 µM, respectively). in inhibition experiments, quinidine or digoxin was used as an activator instead of verapamil at a concentration of 50 µM and 300 µM, respectively.

Data analysis of ATPase experiments. experimental data were analyzed by the use of prism 4.0 (graphpad software, san diego, Ca). to determine eC50 values, a sigmoid dose–response curve was fitted onto the vanadate-sensitive atpase-activity versus concentration plot by nonlinear regression:

where Y is the vanadate-sensitive atpase activity, bottom is the minimal activation observed, top is the maximal activation observed, c is the concentration of the test drug, and log eC50 is the concentration value when the response is halfway between bottom and top.

MDCKII monolayer assay. transport assays across MdCKii–Wt and MdCKii–Mdr1 cells were performed as described.13 Cells were seeded on Millicell 24 (Millipore Kft) plates accord-ing to the manufacturer’s instructions. Quinidine (10 µM) or digoxin (5 µM) was added to the donor compartment. the abCb1 inhibitors, lY-335979 and psC-833 (5, 1, 0.2 µM), were either absent or present in both the basolateral and apical compartments. in experiments with digoxin as a probe, lY-335979 and psC-833 were applied in concentrations of 1 and 5 µM, respectively. in the digoxin MdCKii–Mdr1 monolayer assay, the inhibitory potential of quinidine was also tested at various

concentrations (3, 10, 30, 100 µM). samples were taken from the receptor part after 60 min of incubation in the experiments with quinidine and 120 min in the experiments with digoxin.

Analytical determination of quinidine. Quinidine was meas-ured by high-performance liquid chromatography (hplC) with fluorescence detection. the hplC system was a Merck-hitachi laChrom system, (hitachi high-technologies Corporation, tokyo, Japan) consisting of a d 7000 interface, l 7100 pump, l 7200 autosampler, and l 2480 fluorescence detector. separation of quinidine was achieved using a C18-rp column (phenomenex [torrance, Ca] luna C18, 5 µ, 100 Å, 150 × 2 mm rp) with an isocratic elution profile, consisting of 68% water (0.05% v/v h2so4, 0.01 mol/l sodium octane-1-sulfonate monohydrate) and 32% acetonitrile with an excitation wave-length of 248 nm and an emission wavelength of 460 nm, with a flow rate of 0.4 ml/min. then, 10-µl aliquots of samples were injected into the hplC module. from the raw data of blood and brain dialysates, concentration–time profiles were generated with Microsoft excel and with MicroCal origin, including deter-mination of area under the curves (auCs).

Rat brain primary endothelial cell (RBEC) monolayer assay. rat brain endothelial cells were isolated from 2-week-old rats, as described previously.14,15 pericytes were obtained from cer-ebral microvessels plated onto noncoated dishes. glial cultures were prepared from newborn rats and cultured on poly-l-lysine-coated surfaces.

Construction of the triple co-culture system. rat brain peri-cytes were plated onto the backside of 12-well transwell filters (pore size: 0.4 µm; 1.5 × 104 cells/filter). the next day, endothelial cells were plated onto the upper surface of the filters. after reach-ing confluency, the endothelial monolayer was supplied with 550 nM hydrocortisone, 250 µM Cpt-caMp, and 17.5 µM ro-201724 and placed into dishes containing glial cultures for 24 h.

Permeability measurements. transwell filters containing endothelial cells and pericytes were removed from the plates con-taining the glial culture. filters were washed with ringer-hepes solution (ph 7.4). Quinidine or digoxin was applied at final con-centrations of 0.1 µM and 10 µM, respectively. radiolabeled qui-nidine and digoxin as tracers were also added to the radioactive concentration of 1 µCi/ml. the inhibitors were added together with the test compound at final concentrations of 1 µM (lY-335979 and psC-833) or 100 µM (quinidine). samples were taken from the basolateral or apical side, respectively, at 15, 30, and 60 min, and radioactivity was measured using a liquid scintillation counter (Microbeta; perkinelmer, Waltham, Ma).

Data analysis of monolayer efflux experiments. permeability coefficients and efflux ratios were calculated using the following formulas:

Y BottomTop Bottom

Log EC c= +−

+ −

( )( )1 10 50

Sziráki et al.

888 www.slas.org journal of Biomolecular Screening 16(8); 2011

where dQ is the transported amount, dt is the incubation time, a is the surface of filter, and C0 is the initial concentration.

In vivo assays

Animals, surgical procedures, and administration of drugs. Male Wistar rats (toxiCoop, budapest, hungary) weighing 280 to 360 g were used throughout this study and had free access to food and water. CMa/20 peripheral probes were implanted in the jugular vein, and the rats were placed in a stereotaxic frame for implantation of CMa/l2 brain probes in the frontal cortex (fC) and for performing the microdialysis experiments under chloral hydrate anesthesia (400 mg/kg, intraperitoneal). the stereotaxic coordinates16 for fC with respect to the bregma were ap = +3.0 mm, Ml = 1.5, and dV = –4.5. in retrodialysis experiments, a second brain probe was implanted in the same structure of the opposite side of the brain for perfusing vehicle through the probe. anesthesia during the surgical procedures or the microdialysis experiments was maintained by further injec-tions of chloral hydrate as needed. in experiments on anesthe-tized rats, quinidine and the abCb1 inhibitors and vehicle for the inhibitors were administered intravenously via a catheter implanted in the femoral vein. in retrodialysis experiments with quinidine, a CMa/12 probe in the left fC was perfused with 10 mM psC-833 in 15% cremophor el and 3% ethanol containing cerebrospinal fluid (Csf). the contralateral brain probe was perfused with vehicle for psC-833. in experiments with freely moving animals, a guide cannula was implanted above the tar-geted brain region 4 to 7 days prior to the experiment. in these experiments, the rats were treated with quinidine and with the inhibitors per orally (po). all animal experiments were performed in full compliance with the guidelines of the association for assessment and accreditation of laboratory animal Care international’s expectations for animal use, per the spirit of the licence issued by the directorate for the safety of the food Chain and animal health, budapest and pest County agricultural administrative authority, hungary.

Microdialysis procedures and determination of quinidine in dialysate samples. animals were sampled 90 to 120 min before and 210 to 240 min after intravenous (iV) or po dosing. the peripheral and brain probes were perfused with peripheral per-fusion fluid (ppf) or artificial Csf at a flow rate of 1.0 µl/min using a CMa 102 microdialysis pump. samples were collected in polyethylene microtubes and placed on dry ice at the end of each collection period. after completing an experiment, the blood and brain dialysates were transferred to a deep freezer and kept

at –70º C. dialysate samples were later transferred to a bioana-lytical laboratory and analyzed for concentrations of quinidine by hplC with fluorescence detection as described above.

Data analysis of in vivo experiments. analysis of variance (anoVa) was performed on auCs, Cmax values, and individual brain-to-blood ratios for testing possible treatment–group dif-ferences within the blood and brain dialysate samples followed by duncan’s post hoc test. a paired-sample t test was used for comparing blood and brain means of auCs and Cmax values in the three treatment groups.

reSuLtS

Interaction of quinidine with ABCB1—in vitro assays

effects of quinidine on the function of abCb1 were tested in a membrane assay, in an MdCKii–Mdr1 monolayer, and in a rat brain capillary endothelial cell (rbeC) monolayer assay. in membranes prepared from insect cells overexpressing human abCb1, quinidine increased the vanadate-sensitive atpase activity (Fig. 1A), suggesting that the drug is a likely substrate for abCb1. digoxin, the preferred probe for abCb1-based drug–drug interaction studies, was also characterized in our in vitro assay systems. it has exhibited lower potency and efficacy in stimulating the vanadate-sensitive atpase than quinidine (Fig. 1c,d). the respective eC50 values were 7.8 and 68.5 µM.

to show that this interaction affects penetration of quinidine through monolayers used as bbb models, the permeability of quinidine was tested in MdCKii–Mdr1 and rbeC cells. in the MdCKii monolayer expressing human abCb1, an efflux ratio of ~8 was observed (Fig. 1B), whereas in monolayers pre-pared from wild-type MdCKii cells, the permeability of quini-dine in the basal-to-apical direction was somewhat lower than the permeability in the opposite direction (Fig. 1B). an efflux ratio of 11.6 was found for digoxin in MdCKii–Mdr1 cells (Fig. 1e). interestingly, though, an efflux ratio of 3.5 was observed for digoxin in wt MdCKii cells (Fig. 1e). this is likely due to the effect of the endogenous canine abCb1 expression in this cell line.

in an rbeC monolayer, a 1.5- to 2.0-fold efflux ratio was found in quinidine transcellular transport depending on the length of the incubation time (Fig. 1c). an efflux ratio of 1.6 was observed for digoxin at 15 min that decreased at later time points (Fig. 1F). these data indicate a role for abCb1 in the vectorial transport of quinidine through monolayers. it is also clear that quinidin outperforms digoxin in the assays used.

psC-833 and lY-335979 antagonized the stimulatory effect of quinidine (50 µM) on vanadate-sensitive atpase activity with iC50 values of 46.2 nM and 6.84 nM, respectively, in membranes prepared from human abCb1 overexpressing insect cells (Fig. 2A). neither psC-833 nor lY-335979 had any effect on the vanadate-sensitive atpase activity of the membranes

PdQ

dT A Capp =⋅ ⋅ 0

ERP

Papp B A

app A B

= −

−

( )

( )

Quinidine as an ABcB1 Probe for the Blood–Brain Barrier

journal of Biomolecular Screening 16(8); 2011 www.slas.org 889

FIg. 1. interactions of quinidine and digoxin with abCb1 in vitro. activation of vanadate-sensitive abCb1 atpase by quinidine (A) or digoxin (d). Vectorial transport of quinidine or digoxin in MdCKii monolayers (B, e) and in a rat brain capillary endothelial cell (rbeC) monolayer assay (c, F).

Sziráki et al.

890 www.slas.org journal of Biomolecular Screening 16(8); 2011

FIg. 2. Modulation of quinidine and digoxin transport by psC-833 and lY-335979 in vitro. effects of abCb1 inhibitors on atpase activity stimulated by quinidine (A) or digoxin (d) at concentrations of 50 µM and 300 µM, respectively. Modulation of abCb1-mediated vectorial transport of quinidine or digoxin in the MdCKii–Mdr1 monolayer (B, e) and in the rat brain capillary endothelial cell (rbeC) monolayer assay (c, F). the inhibitory potential of quinidine was also tested in each in vitro assay with digoxin as a probe.

Quinidine as an ABcB1 Probe for the Blood–Brain Barrier

journal of Biomolecular Screening 16(8); 2011 www.slas.org 891

prepared from control insect cell membranes (data not shown). stimulation of vanadate-sensitive atpase activity by digoxin (300 µM) was also effectively inhibited by psC-833 and lY-335979 with iC50 values of 12.6 nM and 3.16 nM, respec-tively (Fig. 2d). Quinidine was less efficacious at inhibition of digoxin-stimulated abCb1 atpase (Fig. 2d).

in MdCKii–Mdr1 monolayers, lY-335979 and psC-833 also inhibited the vectorial transport of quinidine in a concentration-dependent manner (Fig. 2B). lY-335979 was somewhat more potent than psC-833 in MdCKii–Mdr1 cells. in the rbeC monolayer assay, however, the two abCb1 inhibitors were inhibiting the vectorial transport of quinidine with similar potency (Fig. 2c). the inhibitors reduced the efflux ratio of digoxin as potently as observed for quinidine (Fig. 2e,F). Quinidine also inhibited vectorial transport of digoxin in a dose-dependent manner (Fig. 2e).

Interaction of quinidine with ABCB1—in vivo methods

in rat brain microdialysis, concentration–time profiles of qui-nidine in dialysate samples and the pharmacokinetic parame-ters are shown in Figure 3 and table 1 (dose of quinidine was 5 mg/kg, iV). the unbound quinidine in blood dialysate sam-ples reached peak concentration (Cmax) at 1 h posttreatment in

each group of anesthetized rats (Fig. 3). the concentration–time profiles of quinidine from brain dialysates are somewhat different from those of blood dialysate samples. in the psC-833-treated group (4 mg/kg iV, in two divided doses), the Cmax was reached at 2 h posttreatment time. there was an approximately threefold statistically significant difference between the quini-dine auC and the Cmax values of the brain and blood dialysate samples (ratio of auCbrain/auCblood: 0.32) in the absolute con-trol group (Fig. 3A, table 1) and in the pag vehicle group (Fig. 3B, table 1). the brain/blood ratio of auC values was similar when quinidine was applied at a dose of 10 mg/kg in two pilot experiments (data not shown). in the psC-833-treated group (Fig. 3c, table 1), however, the auC and Cmax means in the brain and blood dialysates were very close. this indicates that the inhibition of abCb1 by psC-833 increases the brain exposure to quinidine (table 1).

the auC and the Cmax values determined from brain and blood dialysate samples of the treatment groups were analyzed by anoVa and duncan’s test. there were no statistical differ-ences among the auCs from brain dialysates of the absolute controls and pag vehicle controls. in contrast, the auC of the psC-833-treated group significantly differed from the two con-trol groups (F = 6.50, p < 0.01 and p < 0.05). similarly, in blood dialysate samples, no differences in auCs between the absolute controls and pag vehicle controls were found. the decrease in the auC of quinidine in the psC-833-treated group relative to the control groups was not statistically significant. Cmax values showed a similar trend, except that the decrease of Cmax was significant (table 1).

the brain-to-blood ratios of quinidine levels in individual animals were also analyzed using anoVa and duncan’s test. the auCbrain /auCblood ratio in the psC-833-treated group was significantly higher than in the control (F = 6.51, p < 0.01) or pag vehicle group (p < 0.05). this shows that effluxing of quinidine to the blood by abCb1 is decreased in the presence of psC-833. statistical analysis of the ratios of Cmax values gave a similar tendency (table 1). in pilot experiments, the effects of lY-335979 (20 mg/kg iV, in two divided doses) on the brain penetration of quinidine was determined at two differ-ent doses of quinidine (5 and 10 mg/kg) using the same treat-ment schedule as for psC-833. brain-to-blood ratios of auCs and Cmax values were significantly increased by lY-335979 at both doses of quinidine (data not shown).

to test the dose dependency of the effect of psC-833 on quinidine brain penetration in anesthetized rats, the inhibitor also was applied at a lower dose (2 × 1 mg/kg; Fig. 4). data analysis (anoVa followed by duncan’s test) showed that psC-833 did not increase significantly the brain-to-blood ratios of unbound quinidine at this dose; the effect was significantly weaker than at the higher inhibitor dose (p < 0.05).

in a pilot experiment, quinidine brain exposure and the interaction of quinidine with psC-833 at the bbb were studied by the same dual-probe microdialysis technique in freely moving

FIg. 3. Concentration–time profiles of quinidine in dialysate sam-ples from blood and brain. in the absolute control group (A), the ani-mals received vehicle (saline) as pretreatment at –20 min and quinidine at 0 time (5 mg/kg, intravenous) in saline containing 1.2% ethanol, 8% tween 80, and 2.2% peg 300. in another control group, the animals received vehicle for psC-833 (peg 300/96% ethanol/5% glucose; 55:5:10 in saline) at –20 min and at 0 time together with quinidine (B). in a third group (c), the animals received psC-833 first and then the combination of psC-833 and quinidine. Microdialysis samples were collected every 30 min from –120 to +210 min relative to drug admin-istration. brain probes and peripheral probes were perfused (1 µl/min) with cerebrospinal fluid and peripheral perfusion fluid, respec-tively.

Sziráki et al.

892 www.slas.org journal of Biomolecular Screening 16(8); 2011

rats placed into a movement-responsive animal system. a con-trol animal received pag vehicle treatment 20 min before quinidine administration (50 mg/kg, po). another animal received psC-833 (25 mg/kg, po) prior to coadministrating psC-833 and quinidine (25 and 50 mg/kg, po). the brain-to-blood ratios of unbound quinidine levels were 0.32 and 1.01 in the control and the psC833-treated animals, respectively.

to further investigate the p-gp inhibitor–substrate interac-tions at the bbb, psC-833 was locally applied via retrodialysis to anesthetized and freely moving rats. in an anesthetized rat, psC-833 (10 mM) was perfused via the microdialysis probe in the left frontal cortex (fC), starting 60 min before systemic administration of quinidine (5 mg/kg, iV). the extracellular fluid (eCf) levels of quinidine in the left fC were much higher (Fig. 5) than in the right fC, indicating that p-gp was inhibited at the bbb in the psC-833-perfused side. a similar difference was

table 1. pharmacokinetic parameters of Quinidine in dialysates from brain and blood

Brain Blood Brain/Blood

Group AUC, pmol/mL·h Cmax, pmol/mL AUC, pmol/mL·h Cmax, pmol/mL AUC Cmax

Control 103 ± 15 56 ± 9 328 ± 35 173 ± 11 0.32 ± 0.04 0.34 ± 0.06

pag vehicle 117 ± 11 55 ± 6 280 ± 39 130 ± 18 0.38 ± 0.09 0.44 ± 0.04

psC-833 228 ± 42**,+ 107 ± 13**,++ 208 ± 38 100 ± 17**,+ 1.24 ± 0.31**,++ 1.25 ± 0.34*,+

Values are expressed as mean ± seM (n = 5). statistical analysis was performed by analysis of variance followed by duncan’s multiple-comparison tests. for experimental details, see legend to Figure 3.

*,**statistically significant differences between control versus psC-treated groups at a level of p < 0.05 and p < 0.01, respectively.+,++statistically significant differences between pag vehicle–treated versus psC-treated groups at a level of p < 0.05 and p < 0.01, respectively.

FIg. 4. dose dependency of the effect of psC-833 on brain penetra-tion of quinidine. for methodological details, see the legend to figure 3. **p < 0.01 statistically significant difference compared to the absolute control group; ++p < 0.01 statistically significant difference compared to the pag-vehicle treated group; §p < 0.05 statistically significant dif-ference compared to the group treated with lower dose of psC-833.

FIg. 5. effects of psC-833 applied via retrodialysis on brain pene-tration of quinidine in an anesthetized rat. Vehicle (15% cremophor, 3% ethanol in cerebrospinal fluid) of psC-833 (right side) or psC-833 10 mM (left side) was perfused via microdialysis probes in the frontal cortex of rats with a flow rate of 1 µl/min. Quinidine was administered intravenously in a dose of 5 mg/kg at 0 time. the sample collection started at –90 min and finished at +210 min after quinidine injection. Quinidine levels in the samples from the left frontal cortex were corrected with the average fluorescence values in the samples collected prior to the treatment. there was no fluorescence background in the contralateral dialysate samples collected through vehicle-perfused probe. the results are from one of three experiments with similar trends.

found in the quinidine brain exposure between the psC-833-perfused and untreated fC of a freely moving animal (data not shown).

Quinidine as an ABcB1 Probe for the Blood–Brain Barrier

journal of Biomolecular Screening 16(8); 2011 www.slas.org 893

dIScuSSIon

abCb1 is the most important bbb efflux transporter that protects the brain from xenobiotics. the investigation of barrier function requires a variety of methods preferably using the same probes and inhibitors. even though digoxin is the leading abCb1 probe candidate, it has several disadvantages, such as low ld50 values in rodents. its toxicity and difficulties of detec-tion in dialysate samples hinder its application in microdialysis experiments. to date, no data on digoxin from intracerebral microdialysis experiments have been published. in pilot studies, we applied digoxin iV at doses of 0.5 and 1.0 mg/kg without detectable levels of digoxin in the dialysate samples (data not shown). therefore, we chose quinidine as a potential universal probe for the various in vitro and in vivo bbb assay systems.

in vitro elements (atpase and MdCKii–Mdr1 monolayer assays) of the integrated panel in this study are among the most widely employed in vitro abCb1 assays.17–19 a monolayer assay using primary rbeCs co-cultured with astrocytes and peri-cytes14,15,20,21 completed the in vitro assay panel. for in vivo assays, dual-probe microdialysis and brain retrodialysis tech-niques in combination with peripheral sampling with microdialy-sis probes were used. Microdialysis sampling with simultaneous measurements of unbound concentrations of compounds in the blood and brain eCf over time allows a kinetic analysis of transport processes across the bbb.22 to provide abCb1 specifi-city, abCb1-overexpressing membranes and cell lines, as well as control expression systems, were used in the atpase and MdCKii assays. in the case of rbeC and in vivo systems, trans-porter specificity was ensured by employing abCb1-specific inhibitors psC-83310,11,23,24 and lY-335979.8,24,25

despite published data that brain penetration of quinidine is controlled by abCb16–8 and that it has been used as a substrate for abCb1 in vitro,26 quinidine is still referred to as an inhibi-tor.2,9 our assay panel clearly confirmed that quinidine is an abCb1 substrate with reasonable potency (eC50 = 7.80 µM; Fig. 1A). in this study, quinidine proved to be a more robust probe than digoxin (Figs. 1 and 2).

nevertheless, quinidine is also considered a candidate probe along with digoxin, fexofenadine, and talinolol.4 however, unlike other candidates, quinidine is metabolized. in the assays in the bbb panel, this does not seem to matter as clear abCb1-dependent transport was established in cellular and in the in vivo assays. the quinidine/psC-833 combination worked well both in traditional microdialysis and retrodialysis arrangements. in the absence of abCb1 inhibitors, the auCbrain/auCblood value was around 0.3 (Figs. 3 and 5; table 1). upon addition of the inhibitor, the auCbrain/auCblood ratios were close to 1, which is what is expected from a compound with an intermediate pas-sive permeability (Figs. 3 and 5; table 1). the effect of psC-833 on brain penetration of quinidine was dose dependent (Fig. 4). administration of the vehicle for psC-833 containing

peg-300 caused a slight increase in the brain penetration of quinidine (Fig. 3B). this is in line with earlier findings indicat-ing that peg-300 interferes with the activity of abCb127 simi-larly to some other excipients.28

in sum, quinidine is a good probe to study abCb1 function at the bbb as it works well in membrane-based, cellular, and in vivo studies. it meets the criteria of specificity, sensitivity, and technical feasibility.4 Moreover, quinidine/psC-833 is an abCb1-specific substrate/inhibitor combination applicable to many assay systems both in vitro and in vivo.

AcknoWLedgMentS

expert help by gyuláné berekhelyi and eszter patakiné illés in the experimental procedures, as well as Judit Jánossy, ph.d., and timea rosta, Ms.c., in preparation of the manuscript is acknowledged.

noteS

the work was supported by the hungarian national office for research and technology, grant xttpsrt1 (xenobiotic transporter technology platform therapeutic and toxicological applications) and grant gop 1.3.2. (development of an in vivo technological platform for pharmaceutical applications by enhanc-ing r&d capacities), and the european Community grants eustroKe (health-f2-2008-202213).

reFerenceS

1. schinkel, a. h.; Jonker, J. W. Mammalian drug efflux transporters of the atp binding Cassette (abC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55, 3–29.

2. giacomini, K. M.; huang, s. M.; tweedie, d. J.; benet, l. Z.; brouwer, K. l.; Chu, x.; dahlin, a.; evers, r.; fischer, V.; hillgren, K. M.; et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9, 215–236.

3. Zhang, l.; Zhang, Y. d.; Zhao, p.; huang, s. M. predicting drug-drug interactions: an fda perspective. AAPS J. 2009, 11, 300–306.

4. Ma, J. d.; tsunoda, s. M.; bertino, J. s., Jr.; trivedi, M.; beale, K. K.; nafziger, a. n. evaluation of in Vivo p-glycoprotein phenotyping probes: a need for Validation. Clin. Pharmacokinet. 2010, 49, 223–237.

5. harashima, h.; sawada, Y.; sugiyama, Y.; iga, t.; hanano, M. analysis of nonlinear tissue distribution of Quinidine in rats by physiologically based pharmacokinetics. J. Pharmacokinet. Biopharm. 1985, 13, 425–440.

6. Kusuhara, h.; suzuki, h.; terasaki, t.; Kakee, a.; lemaire, M.; sugiyama, Y. p-glycoprotein Mediates the efflux of Quinidine across the blood–brain barrier. J. Pharmacol. Exp. Ther. 1997, 283, 574–580.

7. starling, J. J.; shepard, r. l.; Cao, J.; law, K. l.; norman, b. h.; Kroin, J. s.; ehlhardt, W. J.; baughman, t. M.; Winter, M. a.; bell, M. g.; et al. pharmacological Characterization of lY335979: a potent Cyclopropy- ldibenzosuberane Modulator of p-glycoprotein. Adv. Enzyme Regul. 1997, 37, 335–347.

Sziráki et al.

894 www.slas.org journal of Biomolecular Screening 16(8); 2011

8. sun, h.; bungay, p. M.; elmquist, W. f. effect of Capillary efflux transport inhibition on the determination of probe recovery during in Vivo Microdialysis in the brain. J. Pharmacol. Exp. Ther. 2001, 297, 991–1000.

9. eyal, s.; hsiao, p.; unadkat, J. d. drug interactions at the blood–brain barrier: fact or fantasy? Pharmacol. Ther. 2009, 123, 80–104.

10. advani, r.; saba, h. i.; tallman, M. s.; rowe, J. M.; Wiernik, p. h.; ramek, J.; dugan, K.; lum, b.; Villena, J.; davis, e.; et al. treatment of refractory and relapsed acute Myelogenous leukemia with Combination Chemotherapy plus the Multidrug resistance Modulator psC 833 (Valspodar). Blood 1999, 93, 787–795.

11. o’brien, M. M.; lacayo, n. J.; lum, b. l.; Kshirsagar, s.; buck, s.; ravindranath, Y.; bernstein, M.; Weinstein, h.; Chang, M. n.; arceci, r. J.; et al. phase i study of Valspodar (psC-833) with Mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children’s oncology group. Pediatr. Blood Cancer 2010, 54, 694–702.

12. barnett, C. J.; huff, b.; Kobierski, M. e.; letourneau, M.; Wilson, t. M. stereochemistry of C-6 nucleophilic displacements on 1,1-difluoro- cyclopropyldibenzosuberanyl substrates: an improved synthesis of Multidrug resistance Modulator lY335979 trihydrochloride. J. Org. Chem 2004, 69, 7653–7660.

13. rajnai, Z.; Mehn, d.; beery, e.; okyar, a.; Jani, M.; toth, g. K.; fulop, f.; levi, f.; Krajcsi, p. abCb1 transports seliciclib (r-roscovitine), a Cyclin-dependent Kinase inhibitor. Drug Metab. Dispos. 2010, 38, 2000–2006.

14. Wilhelm, i.; farkas, a. e.; nagyoszi, p.; Váró, g.; bálint, Z.; Végh, g. a.; Couraud, p. o.; romero, i. a.; Weksler, b.; Krizbai, i. a. regulation of Cerebral endothelial Cell Morphology by extracellular Calcium. Phys. Med. Biol. 2007, 52, 6261–6274.

15. hutamekalin, p.; farkas, a. e.; orbók, a.; Wilhelm, i.; nagyoszi, p.; Veszelka, s.; deli, M. a.; buzás, K.; hunyadi-gulyás, e.; Medzihradszky, K. f.; et al. effect of nicotine and polyaromatic hydrocarbons on Cerebral endothelial Cells. Cell Biol. Int. 2008, 32, 198–209.

16. paxinos, g.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 4th ed.; academic press: new York, 1998.

17. Von richter, o.; glavinas, h.; Krajcsi, p.; liehner, s.; siewert, b.; Zech, K. a novel screening strategy to identify abCb1 substrates and inhibitors. Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379, 11–26.

18. polli, J. W.; Wring, s. a.; humphreys, J. e.; huang, l.; Morgan, J. b.; Webster, l. o.; serabjit-singh, C. s. rational use of in Vitro p-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 2001, 299(2), 620–628.

19. feng, b.; Mills, J. b.; davidson, r. e.; Mireles, r. J.; Janiszewski, J. s.; troutman, M. d.; de Morais, s. M. in Vitro p-glycoprotein assays to

predict the in Vivo interactions of p-glycoprotein with drugs in the Central nervous system. Drug Metab. Dispos. 2008, 36, 268–275.

20. deli, M. a.; abrahám, C. s.; Kataoka, Y.; niwa, M. permeability studies on in Vitro blood–brain barrier Models: physiology, pathology, and pharmacology. Cell Mol. Neurobiol. 2005, 25, 59–127.

21. nakagawa, s.; deli, M. a.; Kawaguchi, h.; shimizudani, t.; shimono, t.; Kittel, a.; tanaka, K.; niwa, M. a new blood–brain barrier Model using primary rat brain endothelial Cells, pericytes and astrocytes. Neurochem. Int. 2009, 54, 253–263.

22. dai, h.; elmquist, W. M. drug transport studies using Quantitative Microdialysis. in: Methods in Molecular Medicine: Vol. 89. The Blood–Brain Barriers: Biology and Research Protocols; nag, s., ed.; humana: totowa, nJ, 2003, pp. 249–264.

23. fellner, s.; bauer, b.; Miller, d. s.; schaffrik, M.; fankhänel, M.; spruss, t.; bernhardt, g.; graeff, C.; färber, l.; gschaidmeier, h.; et al. transport of paclitaxel (taxol) across the blood–brain barrier in Vitro and in Vivo. J . Clin. Invest. 2002, 110, 1309–1318.

24. Choo, e. f.; leake, b.; Wandel, C.; imamura, h.; Wood, a. J.; Wilkinson, g. r.; Kim, r. b. pharmacological inhibition of p-glycoprotein transport enhances the distribution of hiV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 2000, 28, 655–660.

25. dantzig, a. h.; shepard, r. l.; Cao, J.; law, K. l.; ehlhardt, W. J.; baughman, t. M.; bumol, t. f.; starling, J. J. reversal of p-glycoprotein-Mediated Multidrug resistance by a potent Cyclopropyldibenzosuberane Modulator, lY335979. Cancer Res. 1996, 56, 4171–4179.

26. Jain, r.; Majumdar, s.; nashed, Y.; Mitra, a. K. Circumventing p-glycoprotein-Mediated Cellular efflux of Qunidine by prodrug derivatization. Mol. Pharm. 2004, 1, 290–299.

27. hugger, e. d.; audus, K. l.; borchardt, r. t. effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 Cell Monolayers. J. Pharm. Sci. 2002, 91, 1980–1990.

28. Werle, M. polymeric and low Molecular Mass efflux pump inhibitors for oral drug delivery. J. Pharm. Sci. 2008, 97, 60–70.

address correspondence to:István Sziráki, Ph.D.

Laboratory of Microdialysis Solvo Biotechnology

Berlini u. 47-49, Budapest, H-1045, Hungary

E-mail: sziraki@solvo.com